Introduction
Prostaglandins E2 and F2a are normally present in the human lung and bronchi (AnggArd, 1965; Karim, Sandler and Williams, 1967) . Prostaglandin F2a (PGF2.) is released from the lungs of guinea-pigs and rats during anaphylactic reactions (Piper and Vane, 1969) , and in man it contracts bronchial smooth muscle in vitro and in vivo (Sweatman and Collier, 1968; Smith and Cuthbert, 1972) . Asthmatic patients appear to be remarkably sensitive to inhaled PGF2. (Mathe et al., 1973) , and it may be that endogenous PGF2a plays a significant role in the pathogenesis of bronchial asthma.
Aspirin and indomethacin strongly inhibit prostaglandin synthesis (Vane, 1971; Smith and Willis, 1971) and it has been suggested that, thereby, aspirin has a bronchodilator action.
A group of asthmatics, however, appear to be sensitive to aspirin and develop increased airways obstruction within minutes of aspirin ingestion (Samter and Beers, 1967) . This response appears to be a chemically mediated rather than an immunological one, as other analgesics, structurally unrelated to aspirin, have similar effects on these individuals (Smith, 1971 The prostaglandins were extracted essentially as described by Unger, Stamford and Bennett (1971) and separated into PGF and PGE fractions on silicic acid columns (Zusman, Caldwell and Speroff, 1972) . The PGE content was determined by bioassay on the rat stomach strip (Silver et al., 1972) , and the PGF2e content by radioimmunoassay using an antiserum generated against a PGF2a albumin conjugate (Caldwell et al., 1971) .
Results
The changes in the PFTs in response to aspirin ingestion are outlined in Table 2 .
The levels of plasma PGE2 were less than 350 pg/ml, and the levels of plasma PGF2a were less than 175 pg/ml in all the samples studied. In other words, the levels of PGE2 and PGF2a were not raised.
Discussion
It has been suggested that prostaglandin release may play a significant role in the pathogenesis of bronchial asthma (Mathe et al., 1973) . Aspirin ingestion in aspirin-sensitive individuals provokes severe asthmatic attacks and would be expected, therefore, to be associated with raised levels of PGF26. However, from our results, it would appear that only trace amounts of PGE2 and PGF2a are present in the circulation during such attacks, and that some other mechanism is responsible for the production of asthma in these individuals.
On the other hand, these results are insufficient to disprove the hypothesis of Math6 et al. (1973) that release of PGF2, from lung tissue plays a significant part in bronchial asthma. Firstly, in some of the PGF2a by our present methods (sensitivity 0-5 pmol/ml plasma). Secondly, in some patients, PGF2a inhaled at zero time produced an effect which lasted for 1 hr. Since this PGF2a may be metabolized very rapidly, the broncho-constrictor effect could persist longer than the prostaglandin. Smith and Cuthbert (1971) have demonstrated a delay in the onset of the broncho-constrictor effect of PGF2a in healthy volunteers, suggesting that this prostaglandin may itself be releasing another broncho-constrictor agent, or possibly undergoing metabolism to a more active substance.
In order to be certain that there is not a shortlived increase in plasma PGF2a during an asthmatic attack, time-course measurements of PGF2a levels should be done using a continuous sampling technique. It would also be of value to measure the levels of 9,11-dihydroxy-15 ketoprost-5-enoic acid, the major metabolite of PGF2a (Beguin et al., 1972) . idiosyncrasy in patients with aspirin attacks plasma during asthmatic
